ArticleESMO open2026
Long-term outcomes, pathological classification and prognostic factors in localised and advanced appendiceal goblet cell adenocarcinoma following cytoreductive surgery, intraperitoneal and systemic chemotherapy.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAppendiceal goblet cell adenocarcinomas (GCAs) are rare and preferentially spread to the peritoneum. They comprise differing histological patterns with variable prognosis. Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) is offered in specialist centres for eradication of peritoneal metastases, but the role of systemic chemotherapy is unclear. This study aimed to evaluate the long-term outcomes and prognostic factors of GCA patients using the World Health Organisation (WHO) 2019 grading following CRS + HIPEC and the role of systemic chemotherapy. MATERIALS AND
methodsPatient data from a peritoneal tumour centre were identified through a prospective database and histopathology archive (1993-2021). Patients were selected for CRS + HIPEC based on disease distribution and burden. Cases were re-reviewed for histological and two-tiered grading. Systemic chemotherapy was categorised into curative (neo/adjuvant) and palliative intent. The primary endpoint was overall survival (OS).
resultsThere were 210 patients with GCA who had 60% localised disease (M0) and 40% peritoneal metastases (M1) at diagnosis. CRS was carried out on 135 (64%) patients and systemic chemotherapy was given to 85 (40%) patients: 11 (13%) neoadjuvant, 9 (11%) adjuvant and 52 (61%) palliative. After multivariable analysis, positive lymph nodes, peritoneal metastasis, no perforation, no CRS and systemic chemotherapy were associated with increased risk of death (P < 0.05). Re-categorisation of the cohort into two-tiered grading showed improved stratification compared with Tang or WHO 2019 grading. Systemic chemotherapy was associated with benefit for patients with high-grade disease, positive lymph nodes and completeness of cytoreduction score CC1-3 CRS (P < 0.05).
conclusionThis study represents the largest non-registry cohort of appendiceal GCA that evaluates prognostic factors. It outlines outcomes after CRS + HIPEC and provides a comprehensive analysis of the WHO 2019 grading with consideration of a two-tiered system for better risk stratification and selection of patients for systemic chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.